Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study.
about
Surgery for ulcerative colitis: Outcomes in low volume hospitals versus high volume hospitalsAdverse effects of biologics: a network meta-analysis and Cochrane overviewTumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitisTherapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approachesCurrent approaches for optimizing the benefit of biologic therapy in ulcerative colitisBenefit-risk assessment of golimumab in the treatment of refractory ulcerative colitisOptimal management of steroid-dependent ulcerative colitisInflammatory Bowel Disease: An Overview of Immune Mechanisms and Biological TreatmentsAdvances in refractory ulcerative colitis treatment: A new therapeutic target, Annexin A2Review article: applying pharmacokinetics to optimise dosing of anti-TNF biologics in acute severe ulcerative colitisOptimization of the treatment with immunosuppressants and biologics in inflammatory bowel diseaseBiologics in the management of ulcerative colitis - comparative safety and efficacy of TNF-α antagonistsBiomarkers as potential treatment targets in inflammatory bowel disease: A systematic reviewReview article: Infliximab therapy for inflammatory bowel disease--seven years onReview article: dose optimisation of infliximab for acute severe ulcerative colitis.Inflammatory bowel disease: perioperative pharmacological considerations.Tacrolimus or infliximab for severe ulcerative colitis: short-term and long-term data from a retrospective observational studyAll that bleeds is not infliximab-refractory ulcerative colitis.Anti-TNF alpha in the treatment of ulcerative colitis: a valid approach for organ-sparing or an expensive option to delay surgery?Rescue therapy with cyclosporine or infliximab is not associated with an increased risk for postoperative complications in patients hospitalized for severe steroid-refractory ulcerative colitis.Current approaches to the management of new-onset ulcerative colitis.Poorly responsive ulcerative colitis in the hospitalPulse cyclophosphamide therapy for inflammatory bowel disease.European evidence-based Consensus on the management of ulcerative colitis: Current management.Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease.Maintenance of remission with infliximab in inflammatory bowel disease: efficacy and safety long-term follow-up.Defects in mucosal immunity leading to ulcerative colitis.Infliximab: the evidence for its place in therapy in ulcerative colitis.Strategies for the care of adults hospitalized for active ulcerative colitisInfliximab and ulcerative colitis.Medical management of fulminant colitis.A critical assessment of new therapies in inflammatory bowel disease.Review article: medical treatment of severe ulcerative colitis.Promising effect of infliximab on the extent of involvement in ulcerative colitisInflammatory bowel disease: new insights into pathogenesis and treatment.Cause for controversy? Infliximab in the treatment of ulcerative colitis: an update.Infliximab therapy for moderately severe Crohn's disease and ulcerative colitis: a retrospective comparison over 6 years.Infliximab in the treatment of Crohn's disease: a user's guide for clinicians.Treatment of inflammatory bowel disease in childhood: best available evidence.Pros and cons of medical management of ulcerative colitis.
P2860
Q24200174-B3AC9437-59B1-45BB-971F-3D293B901037Q24234197-617F33A9-A95F-47EE-864D-0CD3CD27B79BQ24245033-D3F7AAF0-3A3F-4708-8AEE-DC61160E7A5BQ24806367-F096279F-76C6-4D17-9CB0-3DECF0801908Q26745712-621F6328-7BCF-4495-8969-F3A58B08B534Q26764801-0E3290EA-B1E9-4D25-915F-115738383692Q26773203-3E51FE02-5824-4196-8DEE-28C977C1460EQ26785537-AEC0FC1C-3ECC-48E7-A630-A0DA6997A554Q26798299-8F08848B-457F-400F-AE8D-A845977D8172Q26823221-11072684-CDF9-401B-A46F-41569E584063Q26866940-197C3967-DDFD-42AF-9550-15F9652E3D0BQ26999078-35A2EA82-4D59-43EC-A449-4F27BBA42E69Q28087434-5CC7D59D-99E6-41A0-96D4-4AAF2E293196Q28294134-388E3514-383C-4CBC-82A2-EF9E91AB076DQ30239077-A567FFA3-608E-4EE2-BA3F-0BA702731822Q30502980-EE1E9747-1382-4021-83AC-10A4E4BA6F64Q31004717-5C2E3CA5-035B-4592-A0D7-5B093AD1EAB4Q33408842-F23B25FA-F71A-4C65-B576-49A3F1EB5AB7Q33564081-F59D4178-2A24-4C3A-9692-84BFED64A9E5Q33596959-B4494CB8-CDDB-4EAB-8DF7-8578E523D7E7Q33633288-74079CD5-C623-4825-84F1-3EBD89B68EA4Q33831982-AD8DB5DF-5F95-40FF-892D-E26A2FEC9012Q34013209-D8B33FE1-2F97-4B94-8317-21D24321B855Q34025054-A1160C57-031C-41A2-984D-9BD574E962DCQ34127277-734FBAB4-C337-4D1A-BCAE-D4CE31FB8229Q34225622-AF544C30-5A93-4C2D-A329-B7D89AFC2EC7Q34437552-16757AB1-10A3-4AEF-89EA-EDDCB85CB644Q34449876-72569D5A-E702-475A-9C06-E47987AC8393Q34484121-3A3946DE-C83F-4593-9E18-8273EEACC9F2Q34503548-522E90DA-DFF2-47E6-AFC2-038DC1DB94C4Q34538019-406A08D7-2D59-420A-A689-8C3048D51AD1Q34631399-83C77DFA-0A05-48EE-A332-D5F435F1DDD8Q34669198-0A08FDC9-69F0-4AF4-BF3C-30C0E944B3CDQ34714039-37827B96-C002-4080-802A-8DEEB015739AQ35020743-F41C43AD-3C73-4C96-AC1A-7DA3BE062FD3Q35026302-1959A628-A048-49ED-AD16-071A81C8CA74Q35026410-CF8D77D4-E662-4AA0-B659-5F03454C711EQ35030557-1363BF5E-029D-40CF-80F2-D9BB01A2BC14Q35091746-7AAFDDCD-3A05-44D2-B9DF-38EA2E548095Q35100726-145BC48D-AF1A-4001-96DD-B2AA672A38B8
P2860
Infliximab in the treatment of severe, steroid-refractory ulcerative colitis: a pilot study.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Infliximab in the treatment of ...... rative colitis: a pilot study.
@en
Infliximab in the treatment of ...... rative colitis: a pilot study.
@nl
type
label
Infliximab in the treatment of ...... rative colitis: a pilot study.
@en
Infliximab in the treatment of ...... rative colitis: a pilot study.
@nl
prefLabel
Infliximab in the treatment of ...... rative colitis: a pilot study.
@en
Infliximab in the treatment of ...... rative colitis: a pilot study.
@nl
P2093
P2860
P1476
Infliximab in the treatment of ...... rative colitis: a pilot study.
@en
P2093
Hanauer SB
Podolsky DK
Rutgeerts PJ
Sandborn WJ
P2860
P356
10.1097/00054725-200105000-00001
P577
2001-05-01T00:00:00Z